Market Insights

View our webinar on Managed Care Approaches to Address Unmet Patient Needs in Multiple Sclerosis (MS), a disease affecting nearly 1 million people in the U.S. Despite advancements in treatment, significant gaps remain in access, affordability, and comprehensive care.

Join AMCP for an engaging webinar exploring key considerations in the management and diagnosis of idiopathic hypersomnia (IH).

View our Market Insights webinar that features an enlightening exploration of the intersection between mental health and rare diseases.

The AMCP Poster Abstract Program provides a forum for authors to share their research with the managed care pharmacy community.

People with rare diseases often have mental health challenges related to their health care. These vary by disease, but there are common issues that make it difficult for individuals and their families, including delays in getting diagnosed, not knowing what will happen in the future, having limited treatments, and facing financial difficulties.

View our Market Insights webinar that features a candid conversation with panelists from AMCP's Market Insights Roundtable on Optimizing the Management of Inherited Blood Disorders, Part 2 - a follow-up program to the 2022 Roundtable.

Panel of experts discussing targeted therapies to deliver improved patient outcomes in oncology.

Exploring opportunities to improve the quality of life for those with Amyotrophic Lateral Sclerosis (ALS)

View our Market Insights webinar to explore the latest practice recommendations in the management and treatment of food allergies.

Wet age-related macular degeneration is a condition that can lead to significant vision loss. It is treated with regular injections, which often work well at preventing vision loss but are a burden to patients with the condition.

View our Market Insights webinar to explore strategies to optimize patient outcomes and manage costs in Wet Age-Related Macular Degeneration

Health care leaders will need plans for handling new treatments for inherited blood disorders. This might mean changing benefits for treatments to make sure patients can get gene therapy.